2022
Management of Steroid-Refractory Gastrointestinal Immune-Related Adverse Events
Brongiel S, Rychalsky K, Luon D, Johnson A, Price C, Abdelghany O. Management of Steroid-Refractory Gastrointestinal Immune-Related Adverse Events. Annals Of Pharmacotherapy 2022, 57: 148-155. PMID: 35656843, DOI: 10.1177/10600280221094330.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsInstitutional review boardImmunosuppressive therapyAdverse eventsSymptom resolutionImmune-related adverse eventsSecond-line immunosuppressive therapyRetrospective medical record reviewSecond-line medicationsCommon Terminology CriteriaSecond-line therapySecond-line treatmentMedical record reviewDose of infliximabHigh response rateUniversity Institutional Review BoardGastrointestinal ImmuneIrAE treatmentSteroid failureTerminology CriteriaCheckpoint inhibitorsMost patientsRecord reviewInclusion criteriaPatients
2021
Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era
Wang SY, Juthani PV, Borges KA, Shallow MK, Gupta A, Price C, Won CH, Chun HJ. Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era. The Lancet Microbe 2021, 3: e4-e5. PMID: 34901896, PMCID: PMC8641954, DOI: 10.1016/s2666-5247(21)00306-2.Peer-Reviewed Original ResearchSafety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose
Krantz MS, Kwah JH, Stone CA, Phillips EJ, Ortega G, Banerji A, Blumenthal KG. Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose. JAMA Internal Medicine 2021, 181: 1530-1533. PMID: 34309623, PMCID: PMC8314170, DOI: 10.1001/jamainternmed.2021.3779.Peer-Reviewed Original ResearchCytokine profiles in severe SARS-CoV-2 infection requiring extracorporeal membrane oxygenation support
Kaman K, Azmy V, Chichra A, Britto-Leon C, Price C. Cytokine profiles in severe SARS-CoV-2 infection requiring extracorporeal membrane oxygenation support. Respiratory Medicine Case Reports 2021, 33: 101376. PMID: 33680800, PMCID: PMC7925237, DOI: 10.1016/j.rmcr.2021.101376.Peer-Reviewed Original ResearchExtracorporeal membrane oxygenation supportMembrane oxygenation supportVV-ECMOOxygenation supportCytokine stormVeno-venous extracorporeal membrane oxygenation supportSevere SARS-CoV-2 infectionSARS-CoV-2 infectionVV-ECMO supportRefractory respiratory failureProspective cohort studyCohort of patientsInterleukin-2 receptorCytokine elevationHyperinflammatory stateECMO supportRespiratory failureCohort studyCytokine profileClinical courseInterleukin-10COVID19 patientsUnderlying pathophysiologyInterleukin-6Inflammatory responseAllergy & Immunology Involvement on Multidisciplinary Treatment Team During COVID-19 Pandemic
Azmy V, Kaman K, Price C. Allergy & Immunology Involvement on Multidisciplinary Treatment Team During COVID-19 Pandemic. Journal Of Allergy And Clinical Immunology 2021, 147: ab114. PMCID: PMC7849596, DOI: 10.1016/j.jaci.2020.12.418.Peer-Reviewed Original ResearchCytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19
Azmy V, Kaman K, Tang D, Zhao H, Dela Cruz C, Topal JE, Malinis M, Price CC. Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19. Journal Of Clinical Immunology 2021, 41: 738-747. PMID: 33459964, PMCID: PMC7812117, DOI: 10.1007/s10875-020-00949-6.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedBiomarkersCOVID-19COVID-19 Drug TreatmentCytokine Release SyndromeCytokinesDrug Therapy, CombinationFeasibility StudiesFemaleGlucocorticoidsHospitalizationHumansImmunologic FactorsMaleMiddle AgedRetrospective StudiesSARS-CoV-2Severity of Illness IndexTreatment OutcomeYoung AdultConceptsIL-10 levelsIL-6IL-10Disease severityCytokine profileD-dimerTreatment algorithmCritical SARS-CoV-2 infectionCOVID-19SARS-CoV-2 infectionAdministration of tocilizumabAdmission IL-6Maximum oxygen requirementsTocilizumab-treated patientsElevated IL-6Immune-modulating therapyCritical COVID-19Retrospective chart reviewTertiary care centerIL-6 levelsMean IL-6IL-6 inhibitionAdministration of glucocorticoidsRole of cytokinesCytokine elevation
2020
Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease
Zhou Z, Price CC. Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease. Expert Opinion On Investigational Drugs 2020, 29: 1407-1412. PMID: 33094669, DOI: 10.1080/13543784.2020.1840549.BooksConceptsCytokine release syndromeIL-6 inhibitorsRelease syndromeSafety profileInterleukin-6Mild safety profileRandomized clinical trialsTreatment of patientsAvailable clinical dataCOVID-19COVID-19 diseaseCOVID-19 managementNovel coronavirus pneumoniaHyperinflammatory stateClinical outcomesHealthcare burdenClinical trialsClinical dataObservational studyImmune responseLong-term effectsClinical reportsLiterature searchCoronavirus pneumoniaTocilizumabOptimizing Care for Patients With Adverse Events From Immunotherapeutics.
Sheehan K, Price C, Hafez N. Optimizing Care for Patients With Adverse Events From Immunotherapeutics. The Cancer Journal 2020, 26: 537-542. PMID: 33298725, DOI: 10.1097/ppo.0000000000000492.BooksConceptsImmune checkpoint inhibitorsAdverse eventsCheckpoint inhibitorsImmune therapyGuideline-driven managementMajority of irAEsSteroid-refractory casesRisk patientsOptimal carePredictive biomarkersTumor boardIrAEsWellness clinicPatientsEarly detectionTranslational researchTherapyCareCommon occurrenceInhibitorsImmunotherapeuticsClinicSteroidsImmuneBiomarkersTocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.Peer-Reviewed Original ResearchConceptsCytokine release syndromeTocilizumab-treated patientsSevere diseaseRelease syndromeTocilizumab treatmentInflammatory biomarkersNonsevere diseaseSoluble IL-2 receptor levelsHigh-sensitivity C-reactive proteinIL-2 receptor levelsConsecutive COVID-19 patientsIL-6 receptor antagonistMechanical ventilation outcomesC-reactive proteinCOVID-19 patientsHigher admission levelsRace/ethnicityMV daysVentilation outcomesAdverse eventsChart reviewClinical responseMedian ageWhite patientsClinical outcomesRepurposing antimicrobial stewardship tools in the electronic medical record for the management of COVID-19 patients
Davis MW, McManus D, Koff A, Jaszczur GR, Malinis M, Dela Cruz C, Britto CJ, Price C, Azmy V, Kaman K, Gaston D, Early K, DeWitt M, Song JS, Ortiz C, Juthani-Mehta M, Topal JE. Repurposing antimicrobial stewardship tools in the electronic medical record for the management of COVID-19 patients. Infection Control And Hospital Epidemiology 2020, 41: 1335-1337. PMID: 32507113, PMCID: PMC7308631, DOI: 10.1017/ice.2020.281.Peer-Reviewed Original ResearchAssociation of various primary antibody deficiencies with unique clinical manifestations and T cell profiles.
Shin J, Liauw D, Siddiqui S, Chung E, Price C, Kang I. Association of various primary antibody deficiencies with unique clinical manifestations and T cell profiles. Journal Of Allergy And Clinical Immunology 2020, 145: ab217. DOI: 10.1016/j.jaci.2019.12.257.Peer-Reviewed Original Research
2019
Subtle But Clinically Significant: A Review of Antibody Deficiency in Adults
Harada K, Price C. Subtle But Clinically Significant: A Review of Antibody Deficiency in Adults, Clin Pulm Med. 26(3):71-75 May 2019Books
2018
Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects
Schwab C, Gabrysch A, Olbrich P, Patiño V, Warnatz K, Wolff D, Hoshino A, Kobayashi M, Imai K, Takagi M, Dybedal I, Haddock JA, Sansom DM, Lucena JM, Seidl M, Schmitt-Graeff A, Reiser V, Emmerich F, Frede N, Bulashevska A, Salzer U, Schubert D, Hayakawa S, Okada S, Kanariou M, Kucuk ZY, Chapdelaine H, Petruzelkova L, Sumnik Z, Sediva A, Slatter M, Arkwright PD, Cant A, Lorenz HM, Giese T, Lougaris V, Plebani A, Price C, Sullivan KE, Moutschen M, Litzman J, Freiberger T, van de Veerdonk FL, Recher M, Albert MH, Hauck F, Seneviratne S, Pachlopnik Schmid J, Kolios A, Unglik G, Klemann C, Speckmann C, Ehl S, Leichtner A, Blumberg R, Franke A, Snapper S, Zeissig S, Cunningham-Rundles C, Giulino-Roth L, Elemento O, Dückers G, Niehues T, Fronkova E, Kanderová V, Platt CD, Chou J, Chatila TA, Geha R, McDermott E, Bunn S, Kurzai M, Schulz A, Alsina L, Casals F, Deyà-Martinez A, Hambleton S, Kanegane H, Taskén K, Neth O, Grimbacher B. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects. Journal Of Allergy And Clinical Immunology 2018, 142: 1932-1946. PMID: 29729943, PMCID: PMC6215742, DOI: 10.1016/j.jaci.2018.02.055.Peer-Reviewed Original ResearchConceptsMutation carriersClinical featuresTreatment optionsCTLA4 mutationsCytotoxic T-lymphocyte antigen-4Complex immune dysregulation syndromeNatural killer cell countsT-lymphocyte antigen-4Hematopoietic stem cell transplantationAffected mutation carriersCTLA-4 fusion proteinCTLA-4 insufficiencyMain clinical manifestationsStem cell transplantationBest treatment optionNegative immune regulatorT lymphocyte antigenImmune dysregulation syndromeYears of ageAutoimmune cytopeniasEBV associationEBV reactivationMedian ageClinical manifestationsRapamycin inhibitors
2016
Mimics of Angioedema
Hirsh J, Price C. Mimics of Angioedema. Journal Of Allergy And Clinical Immunology 2016, 137: ab247. DOI: 10.1016/j.jaci.2015.12.892.Peer-Reviewed Original ResearchDiagnosis of Multicentric Castleman's Disease: An Evaluation of a Patient with Polygammopathy
Datta R, Price C. Diagnosis of Multicentric Castleman's Disease: An Evaluation of a Patient with Polygammopathy. Journal Of Allergy And Clinical Immunology 2016, 137: ab227. DOI: 10.1016/j.jaci.2015.12.875.Peer-Reviewed Original Research
2015
Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab—for how long?
Barmettler S, Price C. Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab—for how long? Journal Of Allergy And Clinical Immunology 2015, 136: 1407-1409. PMID: 26277594, DOI: 10.1016/j.jaci.2015.06.035.Peer-Reviewed Original Research444. One-Time Gene Therapy to Prevent Peanut-Induced Anaphylaxis
Pagovich O, Wang B, Price C, Jose C, Kaminsky S, Chiuchiolo M, Crystal R. 444. One-Time Gene Therapy to Prevent Peanut-Induced Anaphylaxis. Molecular Therapy 2015, 23: s176. DOI: 10.1016/s1525-0016(16)34053-9.Peer-Reviewed Original ResearchProfoundly Low Immunoglobulins, Lymphopenia, Thymoma and No Infections
Catanzaro J, Lee A, Price C. Profoundly Low Immunoglobulins, Lymphopenia, Thymoma and No Infections. Journal Of Allergy And Clinical Immunology 2015, 135: ab15. DOI: 10.1016/j.jaci.2014.12.982.Peer-Reviewed Original Research
2014
Expansion Of Circulating T Follicular Helper Cells In CVID Patients With Autoimmune Cytopenias
Romberg N, Hsu I, Price C, Cunningham-Rundles C, Meffre E. Expansion Of Circulating T Follicular Helper Cells In CVID Patients With Autoimmune Cytopenias. Journal Of Allergy And Clinical Immunology 2014, 133: ab162. DOI: 10.1016/j.jaci.2013.12.586.Peer-Reviewed Original Research
2011
Defective Peripheral B Cell Tolerance In Alps Patients With Fas Mutations
Price C, Rao V, Danielian S, Meffre E. Defective Peripheral B Cell Tolerance In Alps Patients With Fas Mutations. Journal Of Allergy And Clinical Immunology 2011, 127: ab226. DOI: 10.1016/j.jaci.2010.12.900.Peer-Reviewed Original Research